Clinical Trials and Research - Completed enrollment for the Phase 2 BESTOW clinical trial with 120 participants, four months ahead of schedule[3] - Positive initial data from the first three islet transplant recipients treated with tegoprubart, with two achieving insulin independence[4] - Anticipated milestones include reporting topline results from the Phase 2 BESTOW trial in Q4 2025 and updated interim data from Phase 1b studies in mid-2025[6] Financial Performance and Funding - Completed an oversubscribed offering, raising $85.0 million in gross proceeds, extending cash runway to the end of 2026[5] - Cash, cash equivalents, and short-term investments totaled $78.2 million as of September 30, 2024, with net proceeds from the October offering adding $79.5 million[7] - Net income for Q3 2024 was $77.0 million, primarily due to a non-cash gain of $96.4 million from changes in fair value of warrant liabilities[9] - Total current assets as of September 30, 2024, were $81.5 million, including $71.4 million in short-term investments[14] - Total liabilities as of September 30, 2024, were $38.5 million, with warrant liabilities decreasing to $24.0 million from $76.2 million in December 2023[15] Expenses and Costs - R&D expenses for Q3 2024 increased to $16.5 million, up from $7.9 million in Q3 2023, driven by clinical development and CMC expenses[7] - General and administrative expenses for Q3 2024 increased to $4.0 million, up from $3.3 million in Q3 2023, driven by professional services and operating expenses[9]

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline results in fourth quarter of 2025 Announced positive initial data from first three subjects with type 1 diabetes treated with tegoprubart as part of immunosuppression regimen following islet transplantation in investigator-initiated trial at UChicago Medicine Announced oversubscribed $85 million underwritten offering, with proceeds expected to extend cash runway to ...

Eledon Pharmaceuticals (NASDAQ: ELDN ) completed enrollment of its phase 2 BESTOW trial using its immunosuppressive drug tegoprubart for the prevention of organ rejection in patients who undergo kidney transplant. Why should investors care about thisHe is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to he ...

IRVINE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced the pricing of its underwritten offering of (i) 18,356,173 shares of its common stock at a price of $3.65 per share and (ii) pre-funded warrants to purchase up to an aggregate of 4,931,507 shares of common stock at a price of $3.649 per pre-funded warrant. The pre-funded warrants will be immediately exercisable and will have an exercise price of $0.001 per share. The gross proceeds from ...

- First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence - Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based immunosuppr ...

IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has successfully completed enrollment for its Phase 2 BESTOW clinical trial, which is designed to assess the safety and efficacy of its investigational immunosuppression therapy tegoprubart for the prevention of organ rejection in patients undergoing kidney transplantation. The trial reached its target enrollment of 120 participants approximately four months earlier than original ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value ELDN Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numb ...

Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of rejection in kidney transplantation 80 participants (two-thirds of projected recruitment) enrolled in Phase 2 BESTOW trial Completed an oversubscribed $50 million private placement; Company expects sufficient liquidity through December 2025 IRVINE, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (Nasdaq: ELDN) today reported recent business highlights for its secon ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Delaware 001-36620 20-1000967 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value ELDN Nasdaq Global Market FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Eledon ...

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. ("Eledon") (NASDAQ: ELDN) today announced that it has enrolled the 80th participant in its ongoing Phase 2 BESTOW trial assessing tegoprubart for the prevention of rejection in kidney transplantation. "As of this week, we have already enrolled two-thirds of the projected study participants across sites in the United States, Europe and Latin America," said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. "We are g ...